Cellectar Biosciences Inc (NASDAQ: CLRB) kicked off on Tuesday, down -1.82% from the previous trading day, before settling in for the closing price of $0.30. Over the past 52 weeks, CLRB has traded in a range of $0.22-$3.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 47.54%. With a float of $45.31 million, this company’s outstanding shares have now reached $46.08 million.
Let’s look at the performance matrix of the company that is accounted for 11 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cellectar Biosciences Inc (CLRB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cellectar Biosciences Inc is 1.67%, while institutional ownership is 11.68%. The most recent insider transaction that took place on Jan 10 ’25, was worth 8,400. In this transaction Chief Operating Officer of this company bought 30,000 shares at a rate of $0.28, taking the stock ownership to the 83,141 shares.
Cellectar Biosciences Inc (CLRB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 47.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.51% during the next five years compared to 40.27% growth over the previous five years of trading.
Cellectar Biosciences Inc (NASDAQ: CLRB) Trading Performance Indicators
Take a look at Cellectar Biosciences Inc’s (CLRB) current performance indicators. Last quarter, stock had a quick ratio of 2.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc (NASDAQ: CLRB) saw its 5-day average volume 0.6 million, a negative change from its year-to-date volume of 1.44 million. As of the previous 9 days, the stock’s Stochastic %D was 53.63%. Additionally, its Average True Range was 0.03.
During the past 100 days, Cellectar Biosciences Inc’s (CLRB) raw stochastic average was set at 5.13%, which indicates a significant decrease from 67.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.14% in the past 14 days, which was lower than the 242.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3099, while its 200-day Moving Average is $1.2182. Nevertheless, the first resistance level for the watch stands at $0.3007 in the near term. At $0.3103, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3202. If the price goes on to break the first support level at $0.2812, it is likely to go to the next support level at $0.2713. The third support level lies at $0.2617 if the price breaches the second support level.
Cellectar Biosciences Inc (NASDAQ: CLRB) Key Stats
The company with the Market Capitalisation of 13.41 million has total of 46,080K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -44,580 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -7,420 K.
